Pharmaceuticals

Viral Vectors and Plasmid DNA Market 2026–2035 expanding with biotechnology innovations

March 25, 2026March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Viral Vectors And Plasmid DNA Market Expected To Change Between 2026 And 2030?

The viral vectors and plasmid dna market size has exhibited strong growth in recent years. It is projected to expand from $1.38 billion in 2025 to $1.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The expansion seen in the historic period can be attributed to factors including limited availability of viral vectors, reliance on research-grade plasmid dna, increasing gene therapy pipelines, growing biopharmaceutical r&d activities, and the adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is projected to experience substantial growth in the upcoming years, reaching $1.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period can be attributed to advancements in clinical-grade and GMP plasmid DNA, the broadening application of viral vectors in treating cancer and infectious diseases, increasing investment in gene therapy, a rising demand for immunotherapy solutions, and the embrace of novel vector platforms like AAV and lentiviral vectors. Significant trends expected in this period include the growing use of plasmid DNA and viral vectors in gene therapy, the extension of viral vector platforms for managing cancer and genetic disorders, an increase in GMP-grade plasmid DNA production for clinical purposes, enhanced research into new adeno-associated and lentiviral vectors, and the incorporation of plasmid DNA and viral vectors into the development of immunotherapies and vaccines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

What Underlying Factors Are Accelerating The Growth Of The Viral Vectors And Plasmid DNA Market?

The increasing occurrence of tuberculosis cases is expected to drive the expansion of the viral vector and plasmid DNA market in the future. Tuberculosis (TB) is a transmissible and potentially severe infectious disease caused by bacteria, primarily affecting the lungs but capable of impacting other bodily systems. Plasmid DNA vaccines are utilized to deliver microbial antigen-coding genes for tuberculosis. These vaccines can be formulated to express particular antigens of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, and are administered through intramuscular injection. For instance, in February 2024, GOV.UK, a UK-based government department, reported that tuberculosis cases in England rose by 10.7% in 2023, increasing from 4,380 in 2022 to 4,850. Consequently, the rising incidence of tuberculosis cases is propelling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Structured Across Different Segments?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

Which Trends Are Shaping The Future Of The Viral Vectors And Plasmid DNA Market?

Leading companies in the viral vectors and plasmid DNA market are intensifying their efforts to launch innovative products, such as helper plasmids, to gain a competitive advantage. A helper plasmid represents a form of plasmid DNA utilized in the production of viral vectors, including adeno-associated viral vectors (AAV), which are commonly employed in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced off-the-shelf pHelper, a helper plasmid aimed at accelerating the process from early discovery through commercial manufacture of adeno-associated virus (AAV)-based gene therapy programs and ensuring secure supplies. As the newest offering among a broad spectrum of contract development and manufacturing organization (CDMO) goods and services, helper plasmids are engineered to protect viral vector packaging in cell and gene therapy operations and simplify intricate supply chains. Adeno-associated viral vectors (AAV), which are frequently utilized in gene therapy, are specifically created using these helper plasmids.

Which Major Players Dominate The Viral Vectors And Plasmid DNA Market?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Каnеkа Соrроrаtіоn, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Read the full viral vectors and plasmid dna market report here:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Which Region Is Projected To Dominate The Viral Vectors And Plasmid DNA Market During The Forecast Period?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral Vectors And Plasmid DNA Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3245&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795